The results of the EXTEND [EXTernal beam radiation to Eliminate Nominal metastatic Disease] Phase II Trial were published in JAMA Oncology this month [1].
{However, many will have seen the results, as presented at ASTRO 2022, & posted by Fish, 6 months ago [2].}
Results
"The study included 87 men (median age, 67 years ...). ... with 5 or fewer mets.
"Median follow-up was 22.0 months (range, 11.6-39.2 months).
"Progression-free survival was improved in the combined therapy arm (median not reached) compared with the hormone therapy only arm (median, 15.8 months;... 13.6-21.2 months) ...
"Eugonadal {progression-free survival} was also improved with {metastasis-directed therapy} (median not reached) compared with the hormone therapy only (6.1 months ... 3.7 months to not estimable)
{Note that the bar for eugonadal (normal production of) testosterone was set very low at 150 ng/dL.}
"Flow cytometry and T-cell receptor sequencing demonstrated increased markers of T-cell activation, proliferation, and clonal expansion limited to the combined therapy arm."
-Patrick